News - Boehringer Ingelheim, Oncology

Filter

Popular Filters

1 to 25 of 37 results

US oncologists prescribing of Boehringer's Gilotrif for NSCLC

25-04-2014

Just six months post-launch in the USA, 49% of surveyed US medical oncologists have prescribed German…

Boehringer IngelheimGilotrifMarkets & MarketingOncologyPharmaceuticalUSA

UK NICE recommends Giotrif and Velcade, but says “no” to added use of Alimta

23-04-2014

People in England and Wales with lung cancer whose tumors test positive for a mutation will now have…

AlimtaBoehringer IngelheimEli LillyGiotrifJohnson & JohnsonNorthern EuropeOncologyPharmaceuticalPricingRegulationUKVelcade

Boehringer Ingelheim’s volasertib granted orphan drug designation for AML

Boehringer Ingelheim’s volasertib granted orphan drug designation for AML

17-04-2014

The US Food and Drug Administration and the European Commission have granted German family-owned drug…

Boehringer IngelheimEuropeGermanyHealth Medical PharmaMajorMedicineOncologyPharmaceuticalPharmacologyRegulationUS Food and Drug AdministrationUSAvolasertib

NICE draft guidance recommends Boehringer Ingelheim’s Giotrif

NICE draft guidance recommends Boehringer Ingelheim’s Giotrif

17-03-2014

UK drugs watchdog the National Institute for Health and care Excellence (NICE) this morning issued new…

Boehringer IngelheimGiotrifNorthern EuropeOncologyPharmaceuticalPricingRegulationUK

IQWiG finds that added benefit of Boehringer’s Giotrif depends on mutation status

IQWiG finds that added benefit of Boehringer’s Giotrif depends on mutation status

19-02-2014

The German Institute for Quality and Efficiency in Health Care (IQWiG), in an early benefit assessment…

Boehringer IngelheimGermanyGiotrifNorthern EuropeOncologyPharmaceuticalPricingRegulation

FORMA meets milestones under Boehringer Ingelheim cancer accord

FORMA meets milestones under Boehringer Ingelheim cancer accord

10-01-2014

US drug discovery company FORMA Therapeutics revealed that it has achieved several discovery milestones…

Boehringer IngelheimFORMA TherapeuticsLicensingOncologyPharmaceuticalResearch

New data support Boehringer’s afatinib in Asian and non-Asian lung cancer patients

New data support Boehringer’s afatinib in Asian and non-Asian lung cancer patients

28-10-2013

Data from two pivotal large-scale Phase III registration studies with German independent drug major Boehringer…

afatinibBoehringer IngelheimGilotrifGiotrifOncologyPharmaceuticalResearch

Boehringer files for EU approval of nintedanib

Boehringer files for EU approval of nintedanib

15-10-2013

Boehringer Ingelheim has submitted a Marketing Authorization Application to the EMA for the approval…

Boehringer IngelheimEuropenintedanibOncologyPharmaceuticalRegulation

More highlights from European Cancer Congress from Boehringer and Roche

More highlights from European Cancer Congress from Boehringer and Roche

30-09-2013

Roche presented new results from a trial of an investigational antibody which have shown encouraging…

Boehringer IngelheimEuropeHerceptinnintedanibOncologyPharmaceuticalResearchRoche

Boehringer’s cancer drug Giotrif gains European marketing authorization

Boehringer’s cancer drug Giotrif gains European marketing authorization

27-09-2013

Boehringer Ingelheim has been granted marketing authorization from the European Commission for Giotrif…

afatinibBoehringer IngelheimEuropeOncologyPharmaceutical

Boehringer Ingelheim gets Breakthrough designation for leukemia candidate

17-09-2013

German pharma major Boehringer Ingelheim has gained Breakthrough Therapy Designation from the US Food…

Boehringer IngelheimEuropeOncologyPharmaceuticalRegulationvolasertib

Gilotrif to debut in the USA in week starting Sept 2

23-08-2013

The US subsidiary of family-owned German drug major Boehringer Ingelheim says that, following last month's…

Boehringer IngelheimGilotrifMarkets & MarketingNorth AmericaOncologyPharmaceutical

IN FOCUS: Boehringer Ingelheim presents its

IN FOCUS: Boehringer Ingelheim presents its "long and healthy" R&D pipeline

02-08-2013

German family-owned drug major Boehringer Ingelheim presented its major pipeline developments at an R&D…

afatinibBoehringer IngelheimDiabetesEuropeInterviewslinagliptinnintedanibOncologyPharmaceuticalResearchRespiratory and Pulmonaryvolasertib

Germany's Bayer and Boehringer both get CHMP backing

29-07-2013

Among a string of positive recommendations revealed last Friday (July 26) by the European Medicines Agency's…

afatinibBayerBoehringer IngelheimEuropeEyleaGiotrifOncologyOphthalmicsPharmaceuticalRegulation

Boehringer Ingelheim's Gilotrif could be leading therapy if it overcomes concerns, says GlobalData

18-07-2013

Family-owned German drug major Boehringer Ingelheim could face "significant challenges" over its first-line…

AstraZenecaBoehringer IngelheimEuropeGilotrifIressaMarkets & MarketingOncologyPharmaceuticalRocheTarceva

US FDA approves Boehringer Ingelheim's first cancer drug

15-07-2013

In what the family-owned German drug major Boehringer Ingelheim hopes is just the first drug to come…

afatinibBiotechnologyBoehringer IngelheimGilotrifNorth AmericaOncologyPharmaceuticalQiagenRegulation

AstraZeneca in oncology partnerships with University of Cambridge, Cancer Research UK and Blackfield

09-07-2013

Anglo-Swedish drug major AstraZeneca (LSE: AZN) has reached agreement with the University of Cambridge…

AstraZenecaBlackfieldBoehringer IngelheimJanssenMerck KGaAolaparibOncologyPharmaceuticalResearch

More highlights from ASCO for: Eisai's Halaven; Boehringer's nintedanib; and Lilly's Alimta

03-06-2013

Among further highlights from the ongoing American Society of Clinical Oncology (ASCO) meeting in Chicago,…

AlimtaBoehringer IngelheimEisaiHalavenLillynintedanibOncologyPharmaceuticalResearch

US FDA approves companion diagnostic for Tarceva, and new indication for the Roche drug

15-05-2013

The US Food and Drug Administration late yesterday (May 14) approved Swiss drug major Roche (ROG: SIX)…

Boehringer IngelheimNorth AmericaOncologyPharmaceuticalQiagenRegulationRocheTarcevaTomtovok

Surveys reveal opportunity for medical community to fully embrace biomarker testing in lung cancer

07-05-2013

Results of two surveys that explored how pulmonologists and pathologists are incorporating biomarker…

Boehringer IngelheimNorth AmericaOncologyPharmaceuticalResearch

Oxford BioThera and Boehringer Ingelheim collaborate; Milestone for Heptares

29-04-2013

The UK's Oxford BioTherapeutics (OBT) and family-owned German drug major Boehringer Ingelheim have entered…

Boehringer IngelheimHeptares TherapeuticsLicensingNeurologicalOncologyOxford BioTherapeuticsPharmaceuticalResearchTakeda Pharmaceuticals

Boehringer Ingelheim starts pivotal trial of volasertib in AML

01-03-2013

German family-owned drug major Boehringer Ingelheim has started a Phase III trial of its polo-like kinase…

Boehringer IngelheimOncologyPharmaceuticalResearchvolasertib

Boehringer Ingelheim's afatinib NDA gets priority review in USA

16-01-2013

The US subsidiary of German independent drug major Boehringer Ingelheim revealed yesterday that the New…

afatinibBoehringer IngelheimNorth AmericaOncologyPharmaceuticalQiagenRegulationTomtovok

1 to 25 of 37 results

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top